Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas (Q46836891)

25 December 2017

title

Identification of anaplastic lymphoma kinase break points and oncogenic mutation profiles in acral/mucosal melanomas (English)

1 reference

25 December 2017

author name string

Hai-Tao Niu

1

1 reference

25 December 2017

Qi-Ming Zhou

2

1 reference

25 December 2017

Fang Wang

3

1 reference

25 December 2017

Qiong Shao

4

1 reference

25 December 2017

Yuan-Xiang Guan

5

1 reference

25 December 2017

Xi-Zhi Wen

6

1 reference

25 December 2017

Li-Zhen Chen

7

1 reference

25 December 2017

Qi-Sheng Feng

8

1 reference

25 December 2017

Wei Li

9

1 reference

25 December 2017

Yi-Xin Zeng

10

1 reference

25 December 2017

Xiao-Shi Zhang

11

1 reference

25 December 2017

publication date

11 July 2013

1 reference

25 December 2017

Pigment Cell & Melanoma Research

published in

1 reference

25 December 2017

volume

26

1 reference

25 December 2017

issue

5

1 reference

25 December 2017

page(s)

646-653

1 reference

25 December 2017

BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site

cites work

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

KIT as a therapeutic target in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

A Network of Cancer Genes with Co-Occurring and Anti-Co-Occurring Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

High throughput mass spectrometry-based mutation profiling of primary uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

BRAF, a target in melanoma: implications for solid tumor drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Large-scale analysis of KIT aberrations in Chinese patients with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

c-Met is a potentially new therapeutic target for treatment of human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

MET receptor sequence variants R970C and T992I lack transforming capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

The use of quantitative real-time reverse transcriptase PCR for 5' and 3' portions of ALK transcripts to detect ALK rearrangements in lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

Differential oncogenic potential of activated RAS isoforms in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

The mutation profiles of common oncogenes involved in melanoma in southern China.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

High-throughput oncogene mutation profiling in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FPCMR.12129

21 January 2018

Identifiers

DOI

10.1111/PCMR.12129

1 reference

25 December 2017

1 reference

25 December 2017